When it comes to child mental health, parents often face tough choices about treatment options. One medication that raises many questions is Latuda—but what really happens when children and teenagers take it? The answers aren’t always straightforward. Some side effects are expected, while others may surprise you. Could these effects influence more than just mood? Let’s explore the hidden layers behind this important concern.
TL;DR
Latuda can help manage mental health conditions in children and teens, but it carries risks. Common side effects include nausea, fatigue, sleep changes, and irritability, while serious issues like mood swings or movement problems may also occur. Long-term use raises concerns about growth and development, making close medical monitoring essential.
Start informed care with Child mental health support
Is Latuda Safe for Pediatric Use in the Long Term?
The use of this medication in children and adolescents requires special caution, as it is not approved for all ages or conditions. While it has shown effectiveness in certain cases, its long-term safety in pediatric populations still raises important questions.
Age restrictions
- Children under 10 should not take lurasidone for depression.
- In specific situations, a professional may decide it is the best option, but this choice must be individualized and closely supervised.
Risks to consider
- Latuda may cause nausea, vomiting, or restlessness in some patients.
- With long-term treatment, monitoring is needed for liver function, possible drug interactions, and potential effects on growth and development.
- Cost may also be a limiting factor in some contexts, especially where no subsidy is available.
Latuda can be helpful and relatively safe, but in children and adolescents its use must be carefully evaluated. Continuous medical supervision is essential to balance therapeutic benefits with potential long-term risks.
Common Physical Side Effects: Nausea, Fatigue, and Restlessness
Lurasidone may cause a variety of physical reactions. Some are mild, while others can be serious and require immediate medical attention.
Common effects
- Nausea and vomiting
- Fatigue or unusual tiredness
- Dizziness
Less common but serious effects
- Allergic reactions: rash, itching, hives, swelling of the face, lips, tongue, or throat.
- High blood sugar: increased thirst, frequent urination, weakness, blurred vision.
- Neuroleptic malignant syndrome: high fever, muscle rigidity, excessive sweating, irregular heartbeat.
- Elevated prolactin: unexpected breast tissue growth, nipple discharge.
- Infections: fever, chills, cough, or sore throat.
- Low blood pressure: dizziness, fainting, blurred vision.
- Swallowing problems: pain or difficulty swallowing.
- Seizures.
- Stroke: sudden numbness, weakness, speech or walking difficulties, loss of balance, severe headache, or vision changes.
- Extrapyramidal symptoms (EPS): uncontrolled movements, muscle rigidity, tremors, loss of coordination, shuffling gait.
Close medical monitoring, reporting changes promptly, and adjusting treatment when necessary are essential for safety and effectiveness.
Weight Gain and Changes in Appetite
Weight gain is a frequent side effect of many antipsychotics, though with Latuda the increase is usually smaller compared to other medications in this class.
Weight gain
- Some patients may experience weight gain, though not all will.
- On average, studies show a modest increase of about 2–3 pounds over several months.
- This effect may be linked to changes in brain centers that regulate appetite and metabolism.
Appetite changes
- Some may notice an increase in appetite, contributing to weight gain.
- Others may not experience significant changes in eating habits.
- Responses vary greatly depending on biological factors and lifestyle.
Regular monitoring of weight and eating patterns in children and adolescents on Latuda is essential.
Emotional and Behavioral Changes: Irritability or Agitation
Latuda treatment can lead to emotional and behavioral changes, ranging from mild symptoms to serious effects that require immediate medical intervention. Recognizing these signals early is vital for safety and proper adjustment of treatment.
| Type of Change | Manifestations | Risk Level |
| Common | Agitation, anxiety, irritability, restlessness, drowsiness, dizziness | Moderate; should be monitored |
| Severe | Severe depression, self-harm or suicidal thoughts, tremors, uncontrollable movements | High; require immediate medical attention |
Emotional and behavioral changes vary in intensity. While mild agitation or irritability may be temporary, severe symptoms pose urgent risks. Constant medical supervision and early reporting of these signs are essential for safe treatment.
Sleep Disturbances: Insomnia or Excessive Drowsiness
Latuda can also cause sleep disturbances, mainly presenting as either insomnia or excessive drowsiness. These effects may impact daily routines and require special attention to ensure safety.
Drowsiness
- Includes excessive sleepiness, fatigue, or sleeping longer than usual.
- May also involve dizziness or vision problems.
- Patients should avoid driving, using machinery, or doing tasks that require full concentration until they know how the medication affects them.
Insomnia
- Some individuals may instead develop difficulty falling or staying asleep.
- This can affect mood, concentration, and school performance in teenagers.
Relation to treatment
Lurasidone belongs to the class of atypical antipsychotics, which act by altering the activity of certain brain chemicals. These changes can improve psychiatric symptoms but also lead to sleep-related side effects.
Potential Long-Term Risks on Growth and Development
When treatment is prolonged, concerns arise about its effects on growth and development in younger patients.
Possible areas of impact
- Physical growth: long-term effects on height and weight remain unclear and need medical monitoring.
- Metabolism: while Latuda generally has a more favorable profile than older antipsychotics, metabolic changes are still possible.
- Emotional and behavioral development: ongoing treatment may influence how patients handle anxiety, irritability, or mood changes.
- Cumulative side effects: risk of movement-related issues such as EPS may increase with time.
Long-term use of Latuda in children and adolescents requires balancing benefits with risks. While it can significantly improve quality of life, constant medical monitoring is necessary to detect potential impacts on growth, metabolism, hormones, and overall development.
Key Takeaways
- Long-term safety: Latuda may be effective in children and adolescents but requires special caution; it is not approved for all ages or conditions. Children under 10 should not use it for depression.
- Common physical side effects: Nausea, vomiting, fatigue, dizziness, and restlessness are frequent.
- Serious risks: Rare but severe reactions include allergic responses, high blood sugar, neuroleptic malignant syndrome, prolactin-related changes, infections, low blood pressure, seizures, stroke, and extrapyramidal symptoms (involuntary movements).
- Weight and appetite changes: Weight gain with Latuda is generally modest (2–3 lbs over several months) and less pronounced than with many other antipsychotics. Appetite changes vary individually.
- Emotional and behavioral effects: Irritability, anxiety, and agitation are common; severe depression, suicidal thoughts, or uncontrolled movements require urgent medical attention.
- Sleep disturbances: Both insomnia and excessive drowsiness may occur, potentially affecting daily routines and school performance.
- Potential long-term developmental risks: Extended use raises concerns about impacts on physical growth, metabolism, emotional regulation, and possible accumulation of movement-related side effects.
- Overall management: Close medical supervision, regular monitoring of physical and emotional health, and careful evaluation of benefits versus risks are essential for pediatric patients taking Latuda.
Sources
- Amerio, A., Giacomini, C., Fusar-Poli, L., Aguglia, A., Costanza, A., Serafini, G., … & Amore, M. (2021). Efficacy and safety of lurasidone in children and adolescents: Recommendations for clinical management and future research. Current Pharmaceutical Design, 27(39), 4062-4069.
https://www.benthamdirect.com/content
- Koukopoulos, A., Calderoni, C., Kotzalidis, G. D., Callovini, T., Moccia, L., Montanari, S., … & Janiri, D. (2025). Lurasidone for Pediatric Bipolar Disorder: A Systematic Review. Pharmaceuticals, 18(7), 979.
https://www.mdpi.com